Core Insights - Beam Therapeutics announced positive updated safety and efficacy data from a phase I/II study for its candidate BEAM-302, targeting alpha-1 antitrypsin deficiency (AATD), with no current approved curative treatments available [1][10] Study Overview - BEAM-302 is being evaluated in an ongoing phase I/II open-label study involving 29 patients, assessing safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy across dose-escalation and expansion cohorts [3] - The study consists of two parts: Part A includes patients with AATD-related lung disease, while Part B includes patients with varying degrees of liver disease, with or without lung involvement [3] Safety and Efficacy Data - Safety data from 26 patients receiving a single dose of BEAM-302 showed a favorable tolerability profile across doses up to 75 mg, with no serious adverse events or dose-limiting toxicities reported [4] - In the multi-dose cohort, three patients experienced higher-grade liver enzyme elevations and Grade 2 infusion-related reactions, all of which were asymptomatic and resolved without intervention [5] - Following a single dose of BEAM-302, patients achieved sustained increases in total AAT levels, with mean concentrations of 16.1 µM in the 60 mg cohort and 14.4 µM in the 75 mg cohort [5] - Treatment with BEAM-302 resulted in substantial reductions in mutant Z-AAT levels, with mean decreases of approximately 84% at the 60 mg dose and 79% at the 75 mg dose, alongside an 80% reduction observed in the multi-dose cohort [8] Treatment Outcomes - After treatment, corrected M-AAT became the predominant circulating form of AAT, accounting for approximately 94% in the 60 mg cohort and 91% in the 75 mg cohort [9] - Patients with AATD-related liver disease in Part B demonstrated consistent efficacy with single doses of 30 mg and 60 mg BEAM-302 [9] Strategic Development Plans - Beam Therapeutics plans to advance BEAM-302 via an accelerated approval pathway, targeting a pivotal cohort start in the second half of 2026, with 60 mg selected as the optimal biological dose for further development [11][12] - The company anticipates enrolling approximately 50 additional patients with AATD-related lung disease to support a future biologics license application [12]